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Lithium and renal 
failure revisited
Whether lithium treatment causes renal 
failure has been a controversial matter, 
largely because of design flaws in previous 
studies. As they report in this issue, Bendz 
et al. tried to provide a better design, using 
health-care statistics from two regions of 
Sweden, accounting for almost a third of 
the country’s inhabitants. In the study pop-
ulation of 2.7 million, 3369 were receiving 
lithium. Among those treated with lithium, 
there were 18 patients receiving treatment 
for end-stage renal disease (ESRD). The 
prevalence of chronic kidney disease in 
the lithium population was 1.2%, certainly 
low but clearly higher than expected. Fur-
ther, the risk of developing ESRD was 
higher in the lithium-treated population. 
See page 219.
Hepatitis B vaccine
Hepatitis B is one of the most serious global 
health hazards, with a significant fraction 
of the world population infected. An effec-
tive vaccine that does not require complex 
dosing regimens is sorely needed. The new 
HB-AS04 elicits rapid and persistent protec-
tion. Dialysis patients especially need such 
long-term protection. In this issue, Surquin 
et al. conducted a randomized open trial in 
dialysis patients not previously vaccinated, 
in which they compared a group vaccinated 
with three doses of the AS02 version with 
another group of similar size and composi-
tion vaccinated with four doses of the AS04 
version. AS02 produced a more rapid and 
persistent seroprotection. Although both 
vaccines are based on the recombinant 
HBV surface antigen, the adjuvants are 
different. The AS02 formulation in this 
study provided better and longer protec-
tion and required fewer booster shots. 
See page 247.
Aging and proteinuria 
in mice
Most mouse laboratory strains are closely 
related, but having been inbred for tens of 
generations, each strain represents a homo-
geneous group. Comparison of these strains 
could lead to new insights into the causa-
tion of disease. As they report in this issue, 
Tsaih et al. performed a haplotype asso-
ciation analysis on 30 such inbred strains. 
Simultaneously, the authors assayed the 
strains’ propensity to develop proteinuria 
as the mice age. Using high-density arrays 
of 63,000 single-nucleotide polymorphisms 
at each time point in the various strains, 
they identified nine loci. These loci were 
then compared with the syntenic posi-
tions in the human genome. Comparison 
of these loci with those associated with 
chronic kidney disease in type I diabetes 
mellitus showed that two of them were the 
same. These loci should provide an excit-
ing new hunting ground for searching for 
a gene that predisposes to kidney disease. 
See page 201.
It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
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